Boardroom Alpha
Boardroom Alpha
ACU · Current Report (Form 8-K) · Filed January 22, 2026

Acme United Corp — Current Report (Form 8-K)

Form
8-K
Filed
January 22, 2026
Period
Jan 22, 2026
Ticker
ACU
Accession
0001193125-26-019610
Boardroom Alpha · Filing insights

Acme United completes asset purchase of My Medic and Rapid Medical for up to $18.7M; $14.6M paid at closing.

About Acme United Corp
Market cap
$160M
1Y TSR
+8.1%
3Y TSR
+20.4%
Board grade
A-
Sector
Consumer Defensive
CEO
Walter C Johnsen
Last annual meeting: Apr 27, 2026 · View full Acme United Corp profile →
8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): January 22, 2026

 

ACME UNITED CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Connecticut

001-07698

06-0236700

(State or other jurisdiction

of incorporation or organization)

(Commission file number)

(I.R.S. Employer

Identification No.)

1 Waterview Dr, Shelton, Connecticut

 

06484

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (203) 254-6060

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $2.50 par value per share

 

ACU

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

 

See the disclosure in Item 2.01 below, “Completion of Acquisition or Disposition of Assets” which is incorporated by reference herein.

 

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

 

 

On January 15, 2026, Acme United Corporation (the “Company”) announced that it had entered into and closed a transaction pursuant to an Asset Purchase Agreement (the “Agreement”) dated January 15, 2026 with SLED Distribution, LLC. d/b/a "My Medic" (“My Medic”), a leading supplier of tactical, trauma and emergency response products, primarily in the direct-to-consumer channel and Rapid Medical, LLC (“Rapid Medical” and, together with My Medic, the “Sellers”), Utah limited liability companies, and certain individual and trust Owners. Pursuant to the Agreement, Acme acquired substantially all of the assets of the Sellers related to the businesses of manufacturing, marketing, and selling emergency and first aid kits, medical packs, tourniquets, and related products (the “Business”).

The assets acquired (“Purchased Assets”) include, among other things, inventory, accounts receivable, prepaid expenses, equipment, intellectual property (including patents, trademarks, trade names, copyrights, domain names, social media accounts, and related goodwill), customer and supplier relationships, permits, and certain contracts. Excluded assets include cash, non-purchased inventory, organizational records, certain contracts and benefit plans, insurance policies, and other items not material to the Business. The Company also assumed certain liabilities under specified contracts and open purchase orders but did not assume any other liabilities of the Sellers, including liabilities related to excluded assets, pre-closing operations, or pre-closing taxes.

 

The maximum purchase price for the Purchased Assets is $18,700,000. At closing, the Company paid $14.6 million in cash to the Sellers. The $4.1 million balance of the purchase price is subject to certain contingencies as follows: (a) $1,000,000, the payment of which is contingent upon the achievement of certain revenue milestones during the twelve months ended December 31, 2027; and (b) $3.1 million, which is subject to a holdback as a non-exclusive source of recovery primarily to satisfy indemnification claims under the Asset Purchase Agreement, which claims must be made within various time periods depending the nature of the claim.

The Agreement contains customary representations, warranties, covenants, and indemnification provisions. Sellers make representations and warranties regarding entity status, authority, ownership of assets, financial statements, absence of undisclosed liabilities, compliance with law, intellectual property, contracts, environmental matters, taxes, and employees. The Agreement also imposes post-closing obligations relating to transition services, employee offers, and assistance with assignments of intellectual property and contracts. In addition, Sellers provide indemnification for breaches of representations and warranties, excluded liabilities, pre-closing taxes, and related matters, subject to negotiated caps, deductibles, and survival periods.

The Agreement is governed by Utah law.

The foregoing summary is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, which is furnished as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Additionally, on January 15, 2026, the Company issued a press release announcing the acquisition of the assets of the Seller; a copy of the press release appears as exhibit 99.1 of this report.

 

 

 

 

 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

 

Exhibit

Number

Description

10.1*

 

Asset Purchase Agreement dated January 15, 2026 by and between Acme United Corporation and My Medic.

99.1

Press release dated January 15, 2026.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

*

 

 

 

 

Confidential treatment has been requested for portions of this exhibit. Certain information has been redacted from this exhibit pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is the type of information that is treated as private or confidential by the Registrant. the Registrant hereby agrees to furnish an unredacted copy of the exhibit to the SEC upon request.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ACME UNITED CORPORATION

 

By

/s/ Walter C. Johnsen

Walter C. Johnsen

Chairman and

Chief Executive Officer

Dated: January 22, 2026

By

/s/ Paul G. Driscoll

Paul G. Driscoll

Vice President and

Chief Financial Officer

Dated: January 22, 2026

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Acme United Corp (ACU)

Reference

Frequently asked questions

When did Acme United Corp file this 8-K?
Acme United Corp (ACU) filed this Current Report (Form 8-K) with the SEC on January 22, 2026. The accession number assigned by EDGAR is 0001193125-26-019610.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Acme United completes asset purchase of My Medic and Rapid Medical for up to $18.7M; $14.6M paid at closing. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Acme United Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Acme United Corp has filed under CIK 2098, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer